Truist Financial Corp Purchases 1,656 Shares of Hims & Hers Health, Inc. $HIMS

Truist Financial Corp raised its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 20.7% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,643 shares of the company’s stock after purchasing an additional 1,656 shares during the period. Truist Financial Corp’s holdings in Hims & Hers Health were worth $481,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Webster Bank N. A. increased its stake in Hims & Hers Health by 229.1% in the second quarter. Webster Bank N. A. now owns 905 shares of the company’s stock valued at $45,000 after purchasing an additional 630 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in Hims & Hers Health in the first quarter valued at approximately $30,000. Parallel Advisors LLC increased its stake in Hims & Hers Health by 175.0% in the second quarter. Parallel Advisors LLC now owns 1,155 shares of the company’s stock valued at $58,000 after purchasing an additional 735 shares in the last quarter. AdvisorNet Financial Inc boosted its holdings in shares of Hims & Hers Health by 127.1% in the second quarter. AdvisorNet Financial Inc now owns 1,340 shares of the company’s stock valued at $67,000 after buying an additional 750 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Hims & Hers Health in the first quarter valued at approximately $41,000. Institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on HIMS shares. UBS Group set a $30.00 price target on shares of Hims & Hers Health in a report on Monday, June 23rd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Hims & Hers Health in a report on Tuesday. Canaccord Genuity Group reiterated a “buy” rating and issued a $68.00 price target on shares of Hims & Hers Health in a report on Friday, September 12th. Wall Street Zen cut shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Finally, Citigroup reiterated a “sell” rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Two research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Hims & Hers Health presently has an average rating of “Reduce” and an average price target of $38.92.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 900 shares of the stock in a transaction on Friday, October 10th. The shares were sold at an average price of $58.25, for a total value of $52,425.00. Following the completion of the sale, the insider owned 291,439 shares in the company, valued at $16,976,321.75. This trade represents a 0.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Irene Becklund sold 8,410 shares of the stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $424,705.00. Following the completion of the sale, the insider owned 1,418 shares of the company’s stock, valued at approximately $71,609. This represents a 85.57% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,561,799 shares of company stock valued at $80,686,085. 13.71% of the stock is owned by company insiders.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $62.79 on Thursday. The stock has a market cap of $14.19 billion, a P/E ratio of 78.49, a P/E/G ratio of 3.69 and a beta of 2.25. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The company has a fifty day moving average price of $50.89 and a two-hundred day moving average price of $48.43. Hims & Hers Health, Inc. has a one year low of $18.33 and a one year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business’s revenue was up 72.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.